pirfenidone has been researched along with Liver Cirrhosis in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 7 (26.92) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Z; Deng, L; Geng, X; Hu, L; Jiao, S; Li, Z; Ren, Q; Wang, B; Yang, Y; Zhang, L; Zhou, Z | 1 |
| Fan, Z; Li, Z; Liang, J; Liu, Y; Lv, Y; Shen, S; Shen, Y; Wang, L; Xu, G; Zhang, F; Zhang, S; Zhang, Y; Zhao, J; Zhou, S; Zhu, Y; Zou, X | 1 |
| AbouSamra, MM; Elgohary, R; Mansy, SS | 1 |
| Huang, N; Jiang, QG; Lin, JQ; Yan, LY; Yang, WZ; Zheng, H | 1 |
| Chen, H; Chen, J; Chen, S; Di, D; Qin, S; Su, G; Wang, K; Yuan, Y; Zhang, Q | 1 |
| Aguilar, JR; Alonso-Campero, R; Bernal-Reyes, R; Gamino, ME; Gasca, F; Gomez-Silva, M; Hernández, L; Hernández, N; la Parra, MG; Muñoz-Espinosa, LE; Peña, P; Pineyro-Garza, E; Poo, JL; Tapia, G | 1 |
| Abdel-Aziz, AH; Abdelghany, TM; Ashour, AA; Salah, MM; Salama, SA | 1 |
| Aguilar-Ramírez, JR; Armendariz-Borunda, J; Bosques-Padilla, F; Cerda, E; Cisneros, L; Cruz, M; Flores-Murrieta, F; Gasca, F; Hernández, L; Mejía-Cuán, L; Muñoz-Espinosa, LE; Patiño, A; Poo, JL; Ramírez-Castillo, C; Tapia, G; Torre, A; Treviño, S; Velázquez, A | 1 |
| Li, CX; Lv, JP; Qu, XH; Shi, Y; Xiao, M; Xie, KJ | 1 |
| Chen, C; Jing, L; Liu, Y; Sun, X; Wang, H; Wen, G; Xu, Y; Yao, X; Zhang, Q; Zhao, L | 1 |
| Chen, G; Kaneko, S; Nagashimada, M; Nagata, N; Ni, Y; Ota, T; Xu, L; Zhuge, F | 1 |
| Oupicky, D; Sun, M; Ullah, A; Wang, K; Wu, P | 1 |
| Groothuis, GM; Olinga, P; Oosterhuis, D; Westra, IM | 1 |
| Alvarez-Álvarez, A; Arellano-Olivera, I; Armendáriz-Borunda, J; Flores-Contreras, L; Lucano-Landeros, S; Mena-Enriquez, MG; Sanchez-Parada, MG; Sandoval-Rodríguez, AS | 1 |
| Armendariz-Borunda, J; Lopez-de la Mora, DA; Lucano-Landeros, S; Macias-Barragan, J; Montoya-Buelna, M; Sanchez-Enriquez, S; Sanchez-Roque, C | 1 |
| Aoudjehane, L; Becquart, J; Bisch, G; Boelle, PY; Calmus, Y; Conti, F; Delelo, R; Housset, C; Paye, F; Scatton, O | 1 |
| Furuke, S; Hata, KI; Ikeda, K; Itoh, M; Komiya, C; Miyachi, Y; Mori, K; Nakabayashi, K; Ochi, K; Ogawa, Y; Shiba, K; Shimazu, N; Suganami, T; Tanaka, M; Tsuchiya, K; Yamaguchi, S | 1 |
| Alvarez-Rodríguez, A; Arellano-Olivera, I; Armendáriz-Borunda, J; Bautista, CA; Bueno-Topete, M; García-Rocha, S; Godoy, J; González-García, I; Islas-Carbajal, MC; Lucano, S; Medina-Preciado, D; Muñoz-Valle, JF; Oregón-Romero, E; Rincón, AR; Salazar, A; Troyo-SanRoman, R; Vázquez-Del Mercado, M | 1 |
| Rockey, DC | 1 |
| Li, XM; Wang, BE; Wang, TL; Zeng, X; Zhao, XY | 1 |
| Grizzi, F | 1 |
| Kossen, K; Pan, L; Ruhrmund, DW; Schaefer, CJ; Seiwert, SD | 1 |
| Armendariz-Borunda, J; Garcia, J; García, L; Grijalva, G; Hernández, I; Margolin, S; Muriel, P; Salazar, A; Sandoval, A; Vera, J | 1 |
| Bendia, E; Benedetti, A; Candelaresi, C; De Minicis, S; Di Sario, A; Macarri, G; Marzioni, M; Omenetti, A; Taffetani, S; Trozzi, L | 1 |
| Alvarez, A; Aréchiga, G; Armendáriz-Borunda, J; Berumen, J; Covarrubias, A; García, L; Islas-Carbajal, MC; Lucano, S; Meza-García, E; Rincón, AR; Salazar, A; Sandoval, AS | 1 |
| Enjoji, M; Iwamoto, H; Kato, M; Nakamuta, M; Nakashima, Y; Nawata, H; Sugimoto, R; Tada, S | 1 |
3 review(s) available for pirfenidone and Liver Cirrhosis
| Article | Year |
|---|---|
Role and New Insights of Pirfenidone in Fibrotic Diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Eye; Fibrosis; Humans; Kidney; Liver Cirrhosis; Myocardium; Pulmonary Fibrosis; Pyridones | 2015 |
Current and future anti-fibrotic therapies for chronic liver disease.
Topics: Angiotensin II; Chronic Disease; Colchicine; Collagen; Extracellular Matrix; Hepatic Stellate Cells; Humans; Interferon-gamma; Ligands; Liver Cirrhosis; PPAR gamma; Pyridones | 2008 |
Antifibrotic activities of pirfenidone in animal models.
Topics: Administration, Oral; Animals; Cardiomyopathies; Disease Models, Animal; Extracellular Matrix Proteins; Humans; Kidney Diseases; Liver Cirrhosis; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta | 2011 |
3 trial(s) available for pirfenidone and Liver Cirrhosis
| Article | Year |
|---|---|
Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study.
Topics: Anti-Inflammatory Agents; Delayed-Action Preparations; Disease Progression; Elasticity Imaging Techniques; Female; Humans; Liver; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Proof of Concept Study; Pyridones; Quality of Life; Standard of Care; Treatment Outcome | 2020 |
Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Cytokines; Fatty Liver; Female; Gene Expression; Hepatitis C, Chronic; Humans; Interleukin-6; Liver; Liver Cirrhosis; Male; Middle Aged; Pyridones; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
A pilot study in patients with established advanced liver fibrosis using pirfenidone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pyridones; Treatment Outcome | 2006 |
20 other study(ies) available for pirfenidone and Liver Cirrhosis
| Article | Year |
|---|---|
Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
Topics: Animals; Chenodeoxycholic Acid; Drug Discovery; Gene Expression Regulation; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Models, Molecular; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Peroxisome Proliferator-Activated Receptors; Protein Binding; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2022 |
Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic niches to inhibit liver metastasis.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Exosomes; Humans; Liver Cirrhosis; Liver Neoplasms; Pancreatic Neoplasms | 2022 |
Innovated pirfenidone loaded lecithin nanocapsules for targeting liver fibrosis: Formulation, characterization and in vivo study.
Topics: Animals; Lecithins; Liver Cirrhosis; Mice; Nanocapsules; Pyridones; Tissue Distribution | 2023 |
Effect and mechanism of pirfenidone combined with 2-methoxy-estradiol perfusion through portal vein on hepatic artery hypoxia-induced hepatic fibrosis.
Topics: 2-Methoxyestradiol; Animals; Collagen; Fibrosis; Hepatic Artery; Hypoxia; Liver Cirrhosis; Matrix Metalloproteinase 2; Perfusion; Portal Vein; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1 | 2023 |
Co-delivery of pirfenidone and siRNA in ZIF-based nanoparticles for dual inhibition of hepatic stellate cell activation in liver fibrotic therapy.
Topics: Hepatic Stellate Cells; Humans; Liver; Liver Cirrhosis; Nanoparticles; RNA, Small Interfering; Tissue Distribution | 2023 |
Prolonged release pirfenidone pharmacokinetics is modified in cirrhosis GENESIS study.
Topics: Area Under Curve; Humans; Liver Cirrhosis; Liver Diseases; Pyridones | 2023 |
Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice.
Topics: Animals; Collagen Type II; Collagen Type IV; Concanavalin A; Disease Models, Animal; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Pyridones; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2019 |
[Effects of pirfenidone on hepatic fibrosis in mice induced by carbon tetrachloride].
Topics: Animals; Carbon Tetrachloride; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred ICR; Pyridones | 2016 |
Dahuang Zhechong Pill suppresses colorectal cancer liver metastasis via ameliorating exosomal CCL2 primed pre-metastatic niche.
Topics: Antineoplastic Agents, Phytogenic; Chemokine CCL2; Colorectal Neoplasms; Drugs, Chinese Herbal; Gene Expression Regulation, Neoplastic; Humans; Liver Cirrhosis; Liver Neoplasms; Macrophages; Neoplasm Metastasis; Neoplasms, Experimental; Pyridones; Pyrrolidinones; Receptors, CCR2 | 2019 |
Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Liver; Liver Cirrhosis; Macrophages; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protective Agents; Pyridones; RAW 264.7 Cells | 2019 |
CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.
Topics: Animals; Apoptosis; Benzylamines; Cell Line; Cell Line, Tumor; Cell Survival; Cyclams; Drug Delivery Systems; Endocytosis; Hepatic Stellate Cells; Heterocyclic Compounds; Humans; Liposomes; Liver Cirrhosis; Mice; p38 Mitogen-Activated Protein Kinases; Pyridones; Rats; Receptors, CXCR4; Signal Transduction; Tissue Distribution; Transforming Growth Factor beta | 2019 |
Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs.
Topics: Animals; Becaplermin; Benzamides; Benzylisoquinolines; Cinnamates; Collagen Type I; Connective Tissue Growth Factor; Depsides; Down-Regulation; Gene Expression; HSP47 Heat-Shock Proteins; Imatinib Mesylate; Liver; Liver Cirrhosis; Male; Models, Biological; Niacinamide; Organ Culture Techniques; Perindopril; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-sis; Pyridones; Pyrimidines; Rats; Rats, Wistar; Rosmarinic Acid; Sorafenib; Transforming Growth Factor beta1; Valproic Acid | 2014 |
Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.
Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cells, Cultured; Collagen Type I; Drug Evaluation, Preclinical; Gene Expression; Humans; In Vitro Techniques; Liver; Liver Cirrhosis; Losartan; Models, Biological; Myofibroblasts; Pyridones | 2016 |
Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.
Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Cells, Cultured; Diet, Western; Disease Models, Animal; Feeding Behavior; Hepatocytes; Humans; Inflammation; Liver; Liver Cirrhosis; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Pyridones; Receptor, Melanocortin, Type 4; Tumor Necrosis Factor-alpha; Up-Regulation | 2017 |
Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment.
Topics: Adult; Aged; Angiotensinogen; Anti-Inflammatory Agents, Non-Steroidal; Base Sequence; DNA Primers; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Male; Mexico; Middle Aged; Plasminogen Activator Inhibitor 1; Polymorphism, Genetic; Pyridones; Transforming Growth Factor beta | 2008 |
Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells.
Topics: Albumins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigen-Antibody Complex; Carbon Tetrachloride; Cells, Cultured; Cytoprotection; Drug Antagonism; Drug Evaluation, Preclinical; Female; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Mice; Mice, Inbred BALB C; Pyridones; Rats; Rats, Wistar | 2009 |
Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Evaluation, Preclinical; Humans; Liver Cirrhosis; Mice; Mice, Inbred BALB C; Pyridones; Rats; Rats, Wistar | 2009 |
Pirfenidone effectively reverses experimental liver fibrosis.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Bile Ducts; Bilirubin; Carbon Tetrachloride; Hydroxyproline; Ligation; Liver; Liver Cirrhosis; Liver Regeneration; Male; Matrix Metalloproteinase 2; Prothrombin; Pyridones; Rats; Rats, Wistar | 2002 |
The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2.
Topics: Animals; Collagen Type I; Down-Regulation; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Pyridones; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1 | 2004 |
Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats.
Topics: Animals; Blotting, Northern; Body Weight; Collagen; Dimethylnitrosamine; Hydroxyproline; Liver Cirrhosis; Male; Pyridones; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta | 2001 |